Manufactures and sells pharmaceutical formulations including Semaglutide products sold under the Semalix brand (injection pens in 2mg, 4mg, and 8mg doses, plus oral tablets), some of which are sourced from third-party manufacturers such as Dr. Reddy's Laboratories and MSN Labs. The business operates across India, the US, and Brazil, and the merger of J.B. Chemicals & Pharmaceuticals into the company became effective on 8 July 2026 with an appointed date of 21 January 2026. In Q1 FY27, the India business grew 19% year-on-year, the US business 36%, and Brazil 27%. For FY26, employee expenses were 19.1% of revenue, other operating expenses 24.0%, raw materials 12.6%, and depreciation 8.0%. Capital expenditure ran at 4.8% of FY26 revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. India business, US business, Brazil business. Multi-geography pharmaceutical formulations business with recent inorganic expansion via JB Chemicals merger
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 |
| EBITDA (ex other income) | 1,946 | 2,842 | 3,456 | 3,697 | 4,470 |
| margin % | 22.9 | 29.5 | 32.2 | 32.1 | 32.0 |
| Owners' profit | 777 | 1,245 | 1,656 | 1,911 | 2,163 |
| EPS, as reported (₹) | 45.93 | 36.79 | 48.94 | 56.47 | 63.92 |
| ROE % · ROCE % | 13.1 · 17.1 | 20.1 · 22.8 | 24.2 · 28.1 | 25.2 · 28.5 | 12.2 · 9.1 |
| Debt / equity (x) | 0.68 | 0.85 | 0.57 | 0.40 | 0.84 |
| Cash from operations | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Capex | (203) | (574) | (433) | (611) | (677) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| Profit before tax | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 |
| Net profit | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 |
| EPS (₹) | 13.37 | 14.88 | 14.71 | 16.19 | 17.45 | 18.77 | 11.51 | 14.87 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L ◆ | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Torrent Pharma to attend three investor forums in September 2026 | board shareholder meetings | low | — | — |
| 9 Sept 2026 · Newspaper ad on special window for physical share dematerialisation | compliance | minimal | — | — |
| 7 Sept 2026 · Postal Ballot approves Shanti Ekambaram as Independent Director | board shareholder meetings | medium | — | — |
| 7 Sept 2026 · Postal Ballot Result: Shanti Ekambaram appointed Independent Director | compliance | minimal | — | — |
| 11 Aug 2026 · Torrent Pharma to attend Emkay Confluence 2026 investor meet on 14 Aug | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Torrent Pharma gets ESG Rating of 70 from NSE Sustainability | business updates | medium | — | — |
| 6 Aug 2026 · Postal Ballot Notice - Dispatch Completed | compliance | minimal | — | — |
| 5 Aug 2026 · Torrent Pharma: Postal Ballot to Appoint Shanti Ekambaram as Independent Director | board shareholder meetings | low | — | — |
| 5 Aug 2026 · Postal Ballot: Appointment of Shanti Ekambaram as Independent Director | board shareholder meetings | medium | — | — |
| 4 Aug 2026 · Q1 FY26-27 Earnings Call Transcript Uploaded on Website | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 79.3 | 28.9 | 147 of 169 | 13% |
| P/B | 9.6 | 3.3 | 145 of 163 | 11% |
| ROCE | 8.0 | 10.8 | 114 of 183 | 38% |
| ROE | 12.2 | 10.4 | 68 of 171 | 61% |
| Debt / Equity | 0.8 | 0.1 | 157 of 171 | 8% |
| EBITDA margin | 33.1 | 17.5 | 24 of 165 | 86% |
| Revenue growth | 54.9 | 16.3 | 18 of 161 | 89% |
| Profit growth | 3.3 | 30.9 | 105 of 158 | 34% |
| Market cap | 168062 | 839 | 3 of 182 | 99% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
